Paper Details

  1. Home
  2. Paper Details

Advances in the treatment of relapsing-remitting multiple sclerosis.

Author: ChouI-Jun, ConstantinescuCris S, IoneteCarolina, TanasescuRadu

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Multiple sclerosis is a chronic disease that affects the central nervous system and is most common in young adults. While several treatments exist, including interferon-β, glatiramer acetate, fingolimod, laquinimod, teriflunomide, dimethyl fumarate, rituximab, ocrelizumab, ofatumumab, daclizumab, alemtuzumab, and mitoxantrone, there are still unmet needs in management. The choice of treatment depends on the individual patient and their specific risk-benefit profile.
Paper Details　
Original Abstract of the Article :
This article reviews and discusses the approved and emerging therapies for multiple sclerosis (MS). MS is a chronic and disabling immune-mediated disease of the central nervous system (CNS) that affects mainly young adults. MS imposes a huge economic burden on healthcare systems and the society. Alt...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.4103/2319-4170.130440

データ提供：米国国立医学図書館（NLM）

Multiple Sclerosis: A Review of Current and Emerging Therapies

Multiple sclerosis (MS) is a chronic and debilitating autoimmune disease that affects the central nervous system. This study provides a comprehensive review of the current and emerging therapies for relapsing-remitting MS, highlighting the advancements and challenges in managing this complex condition. The authors explore various treatment options, including interferon-β, glatiramer acetate, oral medications, monoclonal antibodies, and immunosuppressive agents, offering insights into their efficacy, side effects, and place in the therapeutic algorithm.

New Therapies Offer Hope for Managing MS

The study highlights the expanding armamentarium of therapies available for MS. While currently available treatments have varying degrees of efficacy in reducing relapse risk, new therapies under development hold promise for improving treatment outcomes. The authors emphasize the need for personalized treatment approaches, tailored to individual patient characteristics and disease progression.

Navigating the Desert of MS: Seeking Effective Treatment Strategies

Managing MS requires a multidisciplinary approach, involving a team of healthcare professionals and personalized treatment plans. This research underscores the importance of ongoing research and development to identify new and more effective therapies for this complex disease. Just as a camel navigates the vast and often unforgiving desert, individuals with MS rely on their healthcare team to provide guidance and support on their journey.

Dr.Camel's Conclusion

This study provides a valuable overview of the current and future therapies for MS. Just as a camel navigates the desert, seeking the best routes to reach its destination, researchers and clinicians are continuously searching for new and improved treatments for MS. The study highlights the importance of individualized treatment plans and ongoing research efforts to improve the lives of individuals living with MS.

Date :
  1. Date Completed 2015-04-10
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

24732658

DOI: Digital Object Identifier

10.4103/2319-4170.130440

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.